EDINBURGH, Scotland -- TPP Global Development Ltd (TPP) enters into a collaboration with Sprint Bioscience AB to develop small molecule inhibitors of choline kinase as human therapeutics for the treatment of cancer.
Under the terms of the agreement TPP and Sprint Bioscience will work together to further the development of small molecule inhibitors of choline kinase as human therapeutics for the treatment of cancer.
There will be three presentations of data on ARIAD's investigational targeted therapies, ponatinib and AP26113; and one presentation of work on choline kinase, a discovery program which is not being pursued further at this time.
Title: Small molecule inhibitors of choline kinase lead to reduced phosphocholine levels and induction of apoptosis in cancer cells
Chesney will work with ACT to further refine and advance the preclinical candidates and backup compounds against two exciting and novel cancer targets that are known as 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) and Choline Kinase (CK), both key cancer metabolism targets identified by Dr.
ACT's medicinal chemists have developed over 150 rationally designed, potent compound inhibitors that inhibit choline kinase enzymatic activity, cell proliferation and tumor growth in xenograft studies.
ACT's top priority programs include novel small molecule compound inhibitors for PKFKFB3 and Choline Kinase
, and a novel DNA quadruplex referred to as PU27, which are summarized below:
These programs include 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) and Choline Kinase
Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an exclusive license to develop and commercialize small molecule compound inhibitors of choline kinase
, an enzyme discovered to be required for the survival of tumors by scientists at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center).